Arrowhead Picks Up Drug-Delivery Technology through Alvos Acquisition | GenomeWeb

Arrowhead Research said this week that it has expanded its portfolio of drug-delivery technologies through the acquisition of privately held Alvos Therapeutics for roughly $2.1 million in stock.

According to Arrowhead, Alvos has rights to a platform of proprietary human-derived homing peptides developed by the MD Anderson Cancer Center. These targeting agents can be linked to siRNAs and small molecules to carry drugs to target cells.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PNAS this week: variation patterns in wheat lines, regulatory variation in Capsella grandiflora, and more.

A Rockefeller University researcher is using edited ants to explore complex biological systems, the New York Times writes.

There's a heritable aspect to how much time people spend online, the Los Angeles Times reports.

Stat News reports that Joseph Gulfo is another contender for FDA commissioner.